Stockreport

Alaunos Therapeutics Reports Second Quarter 2022 Financial Results

Alaunos Therapeutics, Inc.  (TCRT) 
PDF Advancing TCR-T Library Phase 1/2 trial targeting KRAS, TP53 and EGFR mutations across six solid tumor indications; plan to present early data in 3Q 2022 at a scientific [Read more]